{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:26Z","timestamp":1793115326396,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with the loss of major histocompatibility complex class II (MHC-II) expression on AML cells. Although the mechanisms by which this occurs are unknown, the loss of antigen presentation by MHC-II may contribute to AML relapse after transplantation. In this study, we performed single-cell RNA sequencing on patient samples with MHC-II loss and observed downregulation of inflammatory signaling pathways, including type I and II interferons and tumor necrosis factor alpha (TNF-\u03b1), in MHC-II\u2013low AML cells compared with MHC-II\u2013high AML cells from the same samples. Treatment with exogenous interferon gamma (IFN-\u03b3) but not IFN-\u03b1 or TNF-\u03b1 restored MHC-II expression in MHC-II\u2013low post-HSCT relapse cells, and IFN-\u03b3 treatment of THP1 cells increased alloreactivity of HLA-mismatched donor T cells in vitro. Because recombinant IFN-\u03b3 has a short half-life in vivo, we tested whether a novel, long-acting pegylated IFN-\u03b3 (peg\u2013IFN-\u03b3) could increase the sensitivity of AML cells to donor T-cell clearance in mouse models. Peg\u2013IFN-\u03b3 treatment was well tolerated in healthy mice and led to more robust upregulation of MHC-II expression compared with recombinant IFN-\u03b3. In addition, pretreatment with peg\u2013IFN-\u03b3 enhanced AML cell clearance by donor T cells in xenografts, raising the possibility that sensitization of AML cells by exogenous long-acting IFN-\u03b3 may be of therapeutic benefit in patients with AML relapsing after HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019670","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:00:47Z","timestamp":1784671247000},"page":"6968-6980","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Long-acting pegylated interferon gamma sensitizes AML cells to killing by donor T cells"],"prefix":"10.1182","volume":"10","author":[{"given":"Vaishali","family":"Basu","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Mannino","sequence":"additional","affiliation":[{"name":"2Children\u2019s Medical Center Research Institute, UT Southwestern, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mpofu","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Struthers","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Carlson","sequence":"additional","affiliation":[{"name":"3Bolder BioTechnology Inc, Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Cox","sequence":"additional","affiliation":[{"name":"3Bolder BioTechnology Inc, Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-3043","authenticated-orcid":false,"given":"David H.","family":"Spencer","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Rettig","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-654X","authenticated-orcid":false,"given":"Matthew J.","family":"Christopher","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026102711123108200_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","article-title":"Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia","volume":"8","author":"Dickinson","year":"2017","journal-title":"Front Immunol"},{"issue":"19","key":"2026102711123108200_bib2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med"},{"issue":"25","key":"2026102711123108200_bib3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N Engl J Med"},{"issue":"12","key":"2026102711123108200_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"2026102711123108200_bib5","doi-asserted-by":"crossref","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"2026102711123108200_bib6","doi-asserted-by":"crossref","first-page":"e1171447","DOI":"10.1080\/2162402X.2016.1171447","article-title":"HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance","volume":"6","author":"Seliger","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"2026102711123108200_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bmt.2014.285","article-title":"Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?","volume":"50","author":"Hamdi","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2026102711123108200_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2018-99-113911","article-title":"Recurrent genetic HLA loss in acute myeloid leukemia relapsed after matched unrelated allogeneic hematopoietic cell transplant","volume":"132","author":"Jan","year":"2018","journal-title":"Blood"},{"issue":"97","key":"2026102711123108200_bib9","doi-asserted-by":"crossref","first-page":"36929","DOI":"10.18632\/oncotarget.26405","article-title":"Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients","volume":"9","author":"Montes","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"2026102711123108200_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2011.07.012","article-title":"Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation","volume":"17","author":"Waterhouse","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2026102711123108200_bib11","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"2026102711123108200_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2026102711123108200_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102711123108200_bib14","doi-asserted-by":"crossref","first-page":"e226114","DOI":"10.1001\/jamanetworkopen.2022.6114","article-title":"Assessment of patient-specific human leukocyte antigen genomic loss at relapse after antithymocyte globulin\u2013based T-cell\u2013replete haploidentical hematopoietic stem cell transplant","volume":"5","author":"Wu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"24","key":"2026102711123108200_bib15","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102711123108200_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"2026102711123108200_bib17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"2026102711123108200_bib18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.bjc.6601602","article-title":"Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-\u03b3 in haematopoietic tumour cells","volume":"90","author":"Morimoto","year":"2004","journal-title":"Br J Cancer"},{"issue":"13","key":"2026102711123108200_bib19","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1128\/MCB.22.13.4781-4791.2002","article-title":"Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation","volume":"22","author":"Morris","year":"2022","journal-title":"Mol Cell Bio"},{"issue":"4","key":"2026102711123108200_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/2643-3230.BCD-24-0342","article-title":"Single-cell transcriptional atlas of human hematopoiesis reveals genetic and hierarchy-based determinants of aberrant AML differentiation","volume":"6","author":"Zeng","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2026102711123108200_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"43","key":"2026102711123108200_bib22","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102711123108200_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-018-0072-9","article-title":"DNMT3A(R882)-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3A(R882C) OCI-AML3 leukemia cell line","volume":"8","author":"Chen","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026102711123108200_bib24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","article-title":"CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression","volume":"168","author":"Spencer","year":"2017","journal-title":"Cell"},{"issue":"4","key":"2026102711123108200_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41375-021-01476-y","article-title":"Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells","volume":"36","author":"Wilson","year":"2022","journal-title":"Leukemia"},{"issue":"22","key":"2026102711123108200_bib26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"New Engl J Med"},{"issue":"7","key":"2026102711123108200_bib28","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1172\/JCI85736","article-title":"Differential requirements for myeloid leukemia IFN-\u03b3 conditioning determine graft-versus-leukemia resistance and sensitivity","volume":"127","author":"Matte-Martone","year":"2017","journal-title":"J Clin Invest"},{"issue":"16","key":"2026102711123108200_bib43","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1158\/1078-0432.CCR-24-0926","article-title":"Missense mutations in Myc box I influence nucleocytoplasmic transport to promote leukemogenesis","volume":"30","author":"Arthur","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"23","key":"2026102711123108200_bib44","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood.V126.23.2458.2458","article-title":"DNMT3A R882H can cooperate with FLT3-ITD to cause AML in mice","volume":"126","author":"Verdoni","year":"2015","journal-title":"Blood"},{"issue":"7104","key":"2026102711123108200_bib45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"key":"2026102711123108200_bib46","first-page":"e54270","article-title":"A detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model","volume":"116","author":"Mopin","year":"2016","journal-title":"JoVE"},{"issue":"3","key":"2026102711123108200_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00205575","article-title":"A phase I trial of recombinant gamma interferon in patients with cancer","volume":"20","author":"Foon","year":"1985","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2026102711123108200_bib34","first-page":"2866","article-title":"Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients","volume":"45","author":"Kurzrock","year":"1985","journal-title":"Cancer Res"},{"issue":"10","key":"2026102711123108200_bib35","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/jir.2013.0067","article-title":"PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice","volume":"34","author":"Fam","year":"2014","journal-title":"J Interferon Cytokine Res"},{"issue":"10","key":"2026102711123108200_bib36","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ccell.2022.09.007","article-title":"Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses","volume":"40","author":"Chan","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"2026102711123108200_bib29","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.4049\/jimmunol.177.6.3865","article-title":"Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility","volume":"177","author":"Green","year":"2006","journal-title":"J Immunol"},{"issue":"6","key":"2026102711123108200_bib37","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov"},{"issue":"20","key":"2026102711123108200_bib30","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2019000453","article-title":"Pegylated interferon-2\u03b1 invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation","volume":"3","author":"Henden","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2026102711123108200_bib31","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1182\/bloodadvances.2021004908","article-title":"Type 1 interferon to prevent leukemia relapse after allogeneic transplantation","volume":"5","author":"Magenau","year":"2021","journal-title":"Blood Adv"},{"key":"2026102711123108200_bib32","doi-asserted-by":"crossref","first-page":"757002","DOI":"10.3389\/fimmu.2022.757002","article-title":"Preemptive interferon-\u03b1 therapy could protect against relapse and improve survival of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: long-term results of two registry studies","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol"},{"issue":"4","key":"2026102711123108200_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/cncr.20883","article-title":"The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation","volume":"103","author":"Safdar","year":"2005","journal-title":"Cancer"},{"issue":"9","key":"2026102711123108200_bib39","doi-asserted-by":"crossref","first-page":"e190655","DOI":"10.1172\/jci.insight.190655","article-title":"IFN-\u03b3and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation","volume":"10","author":"Ito","year":"2025","journal-title":"JCI Insight"},{"issue":"42","key":"2026102711123108200_bib40","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1038\/s41388-022-02455-y","article-title":"Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype","volume":"41","author":"Kang","year":"2022","journal-title":"Oncogene"},{"issue":"4","key":"2026102711123108200_bib41","doi-asserted-by":"crossref","first-page":"452.e1","DOI":"10.1016\/j.jtct.2025.11.039","article-title":"Decitabine conditioning improves natural killer cell maturation and limits CD8+ T cell terminal differentiation post-allogeneic stem cell transplantation in acute myeloid leukemia patients","volume":"32","author":"van Eck van der Sluijs","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"2026102711123108200_bib42","doi-asserted-by":"crossref","first-page":"627946","DOI":"10.3389\/fmed.2021.627946","article-title":"Low-dose decitabine monotherapy reverses mixed chimerism in adult patients after allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen: a pilot phase II study","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6968\/2595240\/blooda_adv-2026-019670-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6968\/2595240\/blooda_adv-2026-019670-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:40Z","timestamp":1793113960000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/6968\/569790\/Long-acting-pegylated-interferon-gamma-sensitizes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":45,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019670","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,15]]}}}